Better Quality of Life Evident in HAE Patients Using Takhzyro in Pivotal Trial

Better Quality of Life Evident in  HAE Patients Using Takhzyro in Pivotal Trial

283153

Better Quality of Life Evident in HAE Patients Using Takhzyro in Pivotal Trial

Treatment with Takhzyro (lanadelumab) significantly improves health-related quality of life in people with hereditary angioedema (HAE), new data from its pivotal clinical trial show. While all dose regimens improved patient outcomes, the approved dose — 300 mg given every two weeks — provided the greatest benefits. Patients on this dose were 7.2 times more likely to achieve a “minimal clinically important difference” in their health-related quality of life, marking the smallest change recorded that is…

You must be logged in to read/download the full post.